Cancer Immunotherapy and Immune Related Cardiac Complications
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 7359
Special Issue Editor
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy has revolutionized cancer treatment and have significantly improved the clinical outcomes of patients with advanced cancers. However, immune checkpoint inhibitors (ICIs) that target PD-1 (programmed cell death protein-1), PD-L1 (programmed cell death protein ligand-1) or/and CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) are commonly associated with acute immune-mediated adverse events. ICIs have become standard of care for melanoma, non-small cell lung cancer, renal cell cancer, and many other malignancies. As the use of immunotherapy increases, an increasing incidence of immune-related toxicities will be encountered. Although more effective than single-agent immunotherapy, the risk of cardiotoxicity is substantially increased with dual immunotherapy. The use of these agents is associated with increased risk of myocarditis, arrhythmias (including heart block and ventricular tachycardia), pericarditis, and vasculitis; also occur along with much more common noncardiac toxicities and concurrent with other chronic inflammatory diseases. The impact of immunotherapy on existing inflammatory diseases is unknown. Moreover, during the current era of COVID-19, which has proven systemic proinflammatory consequences on the heart and other organs, the concomitant use of ICIs for cancer treatment may have more substantial adverse effects on the cardiovascular system. Studies are currently focusing on understanding the mechanisms underlying the development of cardiotoxicity and risk factors, including potential genetic predisposition for immune-related toxicity as a result of ICIs therapy. Finally, given potential fatal cardiac complications with ICIs, studies focusing on identification of prognostic markers that can help in risk stratification are encouraged. Early identification of patients susceptible to immunotherapy-related cardiotoxicity is clinically meaningful, as more careful monitoring and early management can help improve cardiac outcomes.
Dr. Rabea Asleh
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Immunotherapy
- Immune checkpoint inhibitors
- Cancer
- Cardiotoxicity
- Myocarditis
- Prognostic biomarkers
- Predictors
- Inflammatory diseases
- COVID-19
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.